However, side-effects with VA and CBZ were significantly different. Weight gain was particularly troublesome with VA, while somnolence, dizziness, and ataxia required modification of dosage of CBZ. Severe rash noted in 10% of patients taking CBZ in previous adult studies necessitated drug withdrawal in only 3% of children in the present report. Carbamazepine-induced skin rash was reported in 10% of 335 children treated at Toyama Medical University, Japan, and additional reports are cited in <u>Progress in Pediatric Neurology II</u>, PNB Publ, 1994, pp107-109.

VIGABATRIN MONOTHERAPY FOR INFANTILE SPASMS

The successful management of 21 children with infantile spasms and hypsarrhythmia using vigabatin monotherapy is reported from the Alder Hey Children's Hospital, Liverpool, UK. Age at onset of spasms was 3 to 16 months. A symptomatic cause was identified in 17(81%). Spasms were completely controlled in 17(81%) with an initial dose of vigabatrin 25-50 mg/kg/day, increasing to a maximum of 80-120 mg/kg/d in 3-5 days. At a mean 2 year follow-up, 14(67%) remained seizure-free, and vigabatrin was withdrawn in 4 without relapse. Only one patient failed to respond; this child had meningitis at 4 months and spasms were refractory to all AEDs, including ACTH. Transient drowsiness in 2 patients was the only side-effect noted. (Appleton RE A simple, effective and well-tolerated treatment regime for West syndrome. <u>Dev Med Child Neurol</u> Feb 1995;37:185-187). (Respond: Dr Richard E Appleton, Royal Liverpool Children's NHS Trust, Alder Hey Children's Hospital, Eaton Rd, Liverpool Li 2 2AP, UK).

COMMENT. Vigabatrin has replaced ACTH and prednisone as the firstline treatment for West syndrome in the Liverpool Children's Hospital. Dr Verity and colleagues in the UK have been very successful in their organization of a multicenter, comparative trial of sodium valproate and carbamazepine. A similar controlled trial of vigabatrin and ACTH based in Liverpool might be necessary to convince other centers to initiate a change in treatment of infantile spasms.

Of interest, only 4 children (10%) were seizure free following vigabatrin monotherapy for intractable epilepsy in a previous report from the Royal Liverpool Children's Hospital. Complex partial seizures responded partially but myoclonic seizures were not benefited.(Gibbs et al. 1992; see <u>Progress in Pediatric Neurology II</u>, 1994, pp 104-5).

An open, add-on trial of vigabatrin in 20 children with Lennox-Gastaut syndrome, reported from Wien, Austria, showed 85% with a 50-100% reduction in seizure frequency, even after valproate dosage was reduced. Dyskinesia in 1 child was the only side-effect. (Feucht M, Brantner-Inthaler S. <u>Epilepsia</u> 1994;35:993). Serious mood disorders, depression and/or aggression, were the main reason for withdrawing vigabatrin in 9 (12%) of 73 adults with refractory epilepsy treated at the Meer & Bosch Epilepsia 1994;35:999). Vigabatrin results in a significant increase in brain GABA concentration by inhibiting GABA transaminase.

THEOPHYLLINE-INDUCED INFANTILE SPASMS

Infantile spasms and hypsarrhythmia developed in a 6-month-old infant with asthma after 3 days treatment with theophylline at the Royal